We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
Read MoreHide Full Article
The earnings season for the quarter ending September is off to a strong start. Although the momentum has decelerated compared to the first half, it is still encouraging. As of Oct 19, 84 S&P 500 companies reported results.
Per the latest Earnings Preview, total reported earnings were up 19.2% from the year-ago period on 8.4% higher revenues. Among these companies, 82.1% beat earnings estimates and 61.9% surpassed top-line expectations. Overall, S&P 500 revenues and earnings for the third quarter are estimated to increase 7.2% and 19.2%, respectively.
Per the Earnings Trend report, 10 out of 16 Zacks sectors are likely to record double-digit growth in earnings in Q3. The Zacks Medical sector’s companies, comprising pharma biotech as well as medical device companies, which have reported so far, constituting more than one-fifth of the sector’s market capitalization, show year-over-year growth of 14.4% earnings growth and 10.1% sales growth. However, the estimated numbers for full third-quarter earnings and sales growth for this sector is 8.4% and 6.6%, respectively.
Two of the large pharma companies — Johnson & Johnson (JNJ - Free Report) and Novartis (NVS - Free Report) — which reported last week beat sales estimates. While J&J also beat earnings estimates, Novartis’ earnings matched the same. Biogen (BIIB - Free Report) reported strong results, beating estimates on both counts.
The pharma/drug/biotech sectors have been facing issues related to high prices and rising generic/biosimilar competition. However, consistent innovation has brought several new drugs, which helped offset declining sales of many legacy drugs.
Let’s take a look at three pharma/biotech companies that are set to report third-quarter results on Oct 25. Let's see how things are shaping up for this quarter.
Merck,which is scheduled to release earnings before the opening bell, delivered a positive earnings surprise of 2.91% last quarter. Merck’s earnings beat expectations in all the last four quarters with an average positive surprise of 5.25%.
For this quarter, Merck has an Earnings ESP of -0.30% and a Zacks Rank #3 (Hold). The Zacks Consensus Estimate is pegged at $1.16 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Merck’s newer drugs like Keytruda, Gardasil vaccine and Bridion are likely to boost revenues and offset declining sales of diabetes franchise and other key drugs like Zostavax and Zepatier. The label expansions of blockbuster drug, Keytruda, especially in first-line lung cancer, have significantly boosted sales and the trend is likely to continue. Strong demand for Bridion in the United States and launch in China will boost the sales of the drug in the soon-to-be reported quarter. Zostavax is facing competition from Glaxo’s Shingrix. Research and development costs is likely to be higher due to development of Lynparza, Lenvima and some early-stage candidates. (Read more: Merck to Report Q3 Earnings: What's in the Cards?)
Bristol-Myers is scheduled to announceresults before the closing bell.Bristol-Myers beat estimates in three of the past four quarters while missing the same once. The company delivered an average positive earnings surprise of 6.39%.
Bristol-Myers’ top blockbuster drugs, Opdivo and Eliquis, are likely to drive the company’s top-line on the back of strong demand. Label expansion of Opdivo in newer indications including small cell lung cancer has expanded its patient population. However, competitive pressure for Hepatitis C and HIV business and rising operating expenses will hurt the company’s top and bottom lines. (Read more: Is a Beat in Store for Bristol-Myers in Q3 Earnings?)
Our previous article showed that the company was likely to beat on earnings. However, estimates changed thereafter, making surprise prediction difficult.
Bristol-Myers Squibb Company Price and EPS Surprise
The company is expected to report after market close. Gilead beat estimates in three of the past four quarters while missing the same once. The company delivered an average positive earnings surprise of 6.43%.
The company has an Earnings ESP of -1.98% and a Zacks Rank #1.The Zacks Consensus Estimate is pegged at $1.66 per share.
Gilead’s HCV franchise has been facing competitive and pricing pressure, which resulted in lower sales of its two key drugs in the first half. Total sales of this franchise plunged amid new competition and fewer patient starts. The negative trend is expected to continue in the soon-to-be reported quarter. However, the company’s HIV franchise has witnessed strong momentum so far this year on the back of continued uptake of tenofovir alafenamide based products. Genvoya and Truvada from this franchise are likely to be the top drivers and may offset the sales decline in HCV franchise. Gilead is also diversifying its product and pipeline portfolio by foraying into newer technologies and indications. (Read more: Will Gilead HIV Sales Offset HCV Sales Decline in Q3?)
The company is expected to report before market open. Celgene delivered an earnings surprise of 2.86% last quarter. Celgene’s performance has been encouraging with the company reporting positive surprise in all the last four quarters. The average earnings beat over the last four quarters is 2.38%.
The company has an Earnings ESP of -0.56% and a Zacks Rank #2.The Zacks Consensus Estimate is pegged at $2.25 per share.
Celgene’s Revlimid, which is approved in several indications, is likely to be the main growth driver in the to-be reported quarter, driven by expansion in key markets and longer treatment duration. Approval of Pomalyst in combination with Darzalex and dexamethasone for relapsed/refractory myeloma in the United States should propel sales further. Investors expect the company to throw light on the promising candidates in its pipeline. (Read more: What's in Store for Celgene Q3 Earnings?)
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
The earnings season for the quarter ending September is off to a strong start. Although the momentum has decelerated compared to the first half, it is still encouraging. As of Oct 19, 84 S&P 500 companies reported results.
Per the latest Earnings Preview, total reported earnings were up 19.2% from the year-ago period on 8.4% higher revenues. Among these companies, 82.1% beat earnings estimates and 61.9% surpassed top-line expectations. Overall, S&P 500 revenues and earnings for the third quarter are estimated to increase 7.2% and 19.2%, respectively.
Per the Earnings Trend report, 10 out of 16 Zacks sectors are likely to record double-digit growth in earnings in Q3. The Zacks Medical sector’s companies, comprising pharma biotech as well as medical device companies, which have reported so far, constituting more than one-fifth of the sector’s market capitalization, show year-over-year growth of 14.4% earnings growth and 10.1% sales growth. However, the estimated numbers for full third-quarter earnings and sales growth for this sector is 8.4% and 6.6%, respectively.
Two of the large pharma companies — Johnson & Johnson (JNJ - Free Report) and Novartis (NVS - Free Report) — which reported last week beat sales estimates. While J&J also beat earnings estimates, Novartis’ earnings matched the same. Biogen (BIIB - Free Report) reported strong results, beating estimates on both counts.
The pharma/drug/biotech sectors have been facing issues related to high prices and rising generic/biosimilar competition. However, consistent innovation has brought several new drugs, which helped offset declining sales of many legacy drugs.
Let’s take a look at three pharma/biotech companies that are set to report third-quarter results on Oct 25. Let's see how things are shaping up for this quarter.
Merck & Co., Inc. (MRK - Free Report)
Merck,which is scheduled to release earnings before the opening bell, delivered a positive earnings surprise of 2.91% last quarter. Merck’s earnings beat expectations in all the last four quarters with an average positive surprise of 5.25%.
For this quarter, Merck has an Earnings ESP of -0.30% and a Zacks Rank #3 (Hold). The Zacks Consensus Estimate is pegged at $1.16 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Merck’s newer drugs like Keytruda, Gardasil vaccine and Bridion are likely to boost revenues and offset declining sales of diabetes franchise and other key drugs like Zostavax and Zepatier. The label expansions of blockbuster drug, Keytruda, especially in first-line lung cancer, have significantly boosted sales and the trend is likely to continue. Strong demand for Bridion in the United States and launch in China will boost the sales of the drug in the soon-to-be reported quarter. Zostavax is facing competition from Glaxo’s Shingrix. Research and development costs is likely to be higher due to development of Lynparza, Lenvima and some early-stage candidates. (Read more: Merck to Report Q3 Earnings: What's in the Cards?)
Merck & Co., Inc. Price and EPS Surprise
Merck & Co., Inc. Price and EPS Surprise | Merck & Co., Inc. Quote
Bristol-Myers Squibb Company (BMY - Free Report)
Bristol-Myers is scheduled to announceresults before the closing bell.Bristol-Myers beat estimates in three of the past four quarters while missing the same once. The company delivered an average positive earnings surprise of 6.39%.
The company has an Earnings ESP of -0.48% and a Zacks Rank #2 (Buy). The Zacks Consensus Estimate is pegged at earnings of 91 cents per share. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bristol-Myers’ top blockbuster drugs, Opdivo and Eliquis, are likely to drive the company’s top-line on the back of strong demand. Label expansion of Opdivo in newer indications including small cell lung cancer has expanded its patient population. However, competitive pressure for Hepatitis C and HIV business and rising operating expenses will hurt the company’s top and bottom lines. (Read more: Is a Beat in Store for Bristol-Myers in Q3 Earnings?)
Our previous article showed that the company was likely to beat on earnings. However, estimates changed thereafter, making surprise prediction difficult.
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote
Gilead Sciences, Inc. (GILD - Free Report)
The company is expected to report after market close. Gilead beat estimates in three of the past four quarters while missing the same once. The company delivered an average positive earnings surprise of 6.43%.
The company has an Earnings ESP of -1.98% and a Zacks Rank #1.The Zacks Consensus Estimate is pegged at $1.66 per share.
Gilead’s HCV franchise has been facing competitive and pricing pressure, which resulted in lower sales of its two key drugs in the first half. Total sales of this franchise plunged amid new competition and fewer patient starts. The negative trend is expected to continue in the soon-to-be reported quarter. However, the company’s HIV franchise has witnessed strong momentum so far this year on the back of continued uptake of tenofovir alafenamide based products. Genvoya and Truvada from this franchise are likely to be the top drivers and may offset the sales decline in HCV franchise. Gilead is also diversifying its product and pipeline portfolio by foraying into newer technologies and indications. (Read more: Will Gilead HIV Sales Offset HCV Sales Decline in Q3?)
Gilead Sciences, Inc. Price and EPS Surprise
Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote
Celgene Corporation
The company is expected to report before market open. Celgene delivered an earnings surprise of 2.86% last quarter. Celgene’s performance has been encouraging with the company reporting positive surprise in all the last four quarters. The average earnings beat over the last four quarters is 2.38%.
The company has an Earnings ESP of -0.56% and a Zacks Rank #2.The Zacks Consensus Estimate is pegged at $2.25 per share.
Celgene’s Revlimid, which is approved in several indications, is likely to be the main growth driver in the to-be reported quarter, driven by expansion in key markets and longer treatment duration. Approval of Pomalyst in combination with Darzalex and dexamethasone for relapsed/refractory myeloma in the United States should propel sales further. Investors expect the company to throw light on the promising candidates in its pipeline. (Read more: What's in Store for Celgene Q3 Earnings?)
Celgene Corporation Price and EPS Surprise
Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>